Aim: KCNJ6 coding for potassium inwardly-rectifying channels (Kir3.2, GIRK2) is important for opioid receptor transmission. The KCNJ6 rs2070995 AA genotype has been associated with increased opioid analgesic requirements in Japanese. We analyzed its consequences for other opioid effects.
Introduction
Pain as a multi-factorial symptom [1] is modulated by several genes of which so far 296 have been identified in mice (PainGenes Database, http://www.jbldesign.com/jmogil/enter.html [2] , January 15, 2009 ). This has been translated to common human pain only for less than a 10 th of these genes.
Information from additional genes may improve the utility of genotyping information. One gene listed in the PainGenes database as associated with altered opioid antinociception is KCNJ6. It codes for potassium inwardly-rectifying channels, subfamily J, member 6, (Kir3.2, GIRK2). This G protein-coupled channel is important for opioid receptor transmission and is involved in opioid effects [3] on postsynaptic inhibition [3] and mediating a significant component of analgesia [4, 5] .
Genetic variants in KCNJ6 have recently been shown to increase opioid requirements in Japanese patients after abdominal surgery [6] . Considering interethnic differences in opioid effects and pharmacogenetics and in light of a generally poor reproducibility of genetic modulations, new associations are increasingly required to be shown in at least two independent cohorts. To support a functional association of the KCNJ6 rs2070995 G>A single nucleotide polymorphism (SNP) with decreased opioid effects [6] , we have analyzed this pharmacogenetic modulation of opioid effects in data available from three independent cohorts of methadone substituted former heroin addicts [7] , chronic pain patients in tertiary outpatient care [8] and healthy volunteers [9] .
Methods
Assessments were on available data acquired following the Declaration of Helsinki on Biomedical
Research Involving Human Subjects. The University of Frankfurt Medical Faculty Ethics Review Board (and local boards in cohort two [8] ) approved the study protocols, and written informed consent was obtained from all subjects before the assessments.
Study cohorts
The first available cohort [7] consisted of a random sample of 59 unrelated caucasian men and 26
women (aged 22 to 58 years, mean age ± standard deviation of 35.4±8.5 years, body weight 38 to 103 kg, mean 65.9±12.5 kg) who were on methadone substitution therapy at a drug users outpatient center ("Malteser Drogenambulanz Schielestraße", Frankfurt am Main, Germany) because of heroin addiction and fulfilled the criteria of DSM-IV-TR® for opioid-related disorders, codes 305.50
"Abuse" and 304.00 "Dependence". At the start of therapy racemic methadone hydrochloride oral solution (6-dimethylamino-4,4-diphenyl-heptan-3-one hydrochloride, Methaddict®, Addicare Arzneimittel GmbH, Emmerich, Germany) was administered once daily at a dose of 30, 40 or 50 mg, selected by the investigator to meet the individual patients requirements. The dosage was then gradually adapted according to the clinical picture and therapy success, including the assessment of withdrawal symptoms such as sweating or sleepiness. The maximum dose was not limited by any guideline but adapted according to the particular patient's needs. Daily methadone doses were available for the predefined observation period of 12 months following initiation of substitution therapy.
The second available cohort was a random sample of 156 men and 196 women, aged 58.5 ± 14.6 years, treated with opioids for 1 -600 months (63.4 ± 92.4 months) for pain at three different University outpatient centers of tertiary care [8] . Reasons for opioid treatment were cancer pain (n = 47), craniofacial pain (n = 10), inflammatory pain (n = 19), mechanical low back pain (n = 87), musculoskeletal pain (n = 45), neuropathic pain (n = 109), somatoform pain disorders (n = 5) and other kinds of chronic pain, e.g., posttraumatic or chronic post surgery pain (n = 30). Opioids administered were tilidine or tramadol (n = 81 1 each), morphine (n = 74), fentanyl (n = 55), buprenorphine (n = 41), oxycodone (n = 38), hydromorphone (n = 14), dihydrocodeine (n = 2), and levomethadone or piritramide (n = 1 each). In this cross-sectional assessment opioid doses and current 24-h pain intensity according to an 11-point numerical rating scale ranging from 0, "no pain", to 10, "maximum pain", were recorded once at enrolment.
The third cohort was available from a single-occasion open-label study [9] with light of 13.6 Lux effused by two computer screens [9] .
Genetic Analyses
The main aim of this study was the verification of a recently proposed association of the KCNJ6 variant rs2070995G>A with reduced opioid effects, which had been concluded from increased postoperative opioid dosing requirements [6] . To diagnose this single nucleotide polymorphism (SNP), genomic DNA was extracted from venous blood on a BioRobot EZ1 workstation applying the blood and body fluid spin protocol provided in the EZ1 DNA Blood 200 µl Kit (Qiagen, Hilden, Germany).
The KCNJ6 polymorphism was screened for by means of a newly developed and validated Pyrosequencing TM assay on a PSQ 96 MA System (Qiagen, Hilden, Germany), with assay details given in the online materials. Since a haplotype composed of KCNJ6 rs2070995/rs6517442 had been suggested to be functional [6] Figure 3 ).
Statistics

KCNJ6 genetics
The correspondence between the observed number of homozygous and heterozygous individuals and the numbers expected from the Hardy-Weinberg equilibrium was checked by means of χ 2 goodness-of-fit tests. SNPs with a minor allelic frequency of ≥5% were included in in-silico haplotype analysis using the PHASE computer software (version 2.1.1 for Linux [11] ). Linkage disequilibrium (parameters D' and r 2 ) between SNPs found at allelic frequencies ≥5% was analyzed using the Haploview software (version 4.2 [12] ). Cohorts were compared with respect to allelic frequencies employing χ 2 statistics (basic allele test, i.e., allelic frequency comparisons) with the SVS computer software (version 7.1.1 for Linux, Golden Helix, Inc., Bozeman, USA).
Genotype-phenotype associations
Since the KCNJ6 rs2070995 G>A SNP was reported to be functional only in homozygous carriers of the minor A allele [6] , in this verificatory assessment genotype comparisons were done for AA versus AG/GG groups. This focused on the SNP and not the also reportedly functional haplotype because molecular consequences had been shown only for the SNP. Pharmacogenetic association analysis was done at an exploratory level for the haplotype, however, as a separate analysis needed for discussion and not as part of the main analysis.
Methadone substitution therapy
Parameters of methadone substitution therapy analyzed for genetic influences were (i) the average daily dose during the first year of treatment, (ii) the maximum daily methadone dose, averaged per month, during the first year of treatment and (iii) the time in months when that maximum dose 
Analgesic effects of opioids
Parameters of opioid pain therapy analyzed for genetic influences were (i) the daily opioid dose and (ii) the actual 24-h pain score. Since several different opioids had been administered, doses were converted to oral morphine equivalents (OME) [8, 13] . Association analysis of the KCNJ6 rs2070995 SNP with the opioid dose and the 24-h pain score was done by t-tests as above.
Miotic effects of levomethadone
Parameters of pupil size assessment analyzed for genetic influences were (i) the maximum miotic effects calculated as percent changes from baseline and (ii) the areas under the percent-change in pupil diameter from baseline versus time curve (AUC) calculated using the linear trapezoidal rule.
Genotype comparisons of maximum miosis and AUCs were done by means of t-tests (rs2070995 AA versus AG/GG).
Immunohistochemistry
Since pupil size data suggested that rs2070995 has no effect on levomethadone induced miosis, we investigated whether Kir3.2 is absent from the Edinger-Westphal nucleus, as it has been shown for Kir2.3 [14] . The Edinger-Westphal nucleus signals parasympathetic information to the ciliary ganglion, thus representing the output nucleus for constriction of the eye's sphincter pupillae muscle leading to miosis. Expression analysis was done in rat brains. All animals were handled following the German animal protection laws and were approved by the governmental authorities. Adult
Wistar rats (Charles River, Sulzfeld, Germany) were deeply anesthetized and fixed via transcardial perfusion with 4% paraformaldehyde, 0.05% glutaraldehyde and 0.2% picric acid in 0.1 M phosphate buffer, pH 7.4. Brains were dissected, cryoprotected in 0.8 M sucrose in PBS and shock-frozen as previously described [15] . Free-floating 20 µm coronal cryostat sections were preincubated in 10% normal goat serum (NGS) containing 0.3% Triton X-100 for 30 min at room temperature, incubated with anti-Kir3.2 primary antibody (diluted in 0.3% Triton X-100 in 10% NGS) for 36 hours at 4°C, and biotinylated goat anti-rabbit IgG secondary antibody (Vector Laboratories, Peterborough, UK, 1:2000 in 0.2% bovine serum albumin in PBS) for 20 hours at 4°C. Antibodies were detected according to the manufacturer protocol using the Vectastain Elite ABC kit (Vector Laboratories) and visualized with nickel-enhanced 3,3'-diaminobenzidine tetrahydrochloride reaction [15] . Production and extensive characterization of the polyclonal monospecific affinity-purified anti-Kir3.2 antibody was described previously [16] .
Results
Genotype-phenotype associations
Methadone substitution therapy
Both the average and the maximum daily methadone doses during the first year of substitution therapy were significantly larger in homozygous carriers of the KCNJ6 rs2070995 A allele (n = 4, 
Analgesic effects of opioids
The opioid doses followed more a log-normal than a normal distribution. Opioid dosing demands in homozygous carriers of the KCNJ6 rs2070995 A allele (n = 17, opioid dose 2.03 ± 0.45 log mg OME/d) tended to be higher than those of the other chronic pain patients (1.81 ± 0.52 log mg OME/d, p = 0.093, Cohen's d = 0.42) (Figure 1 ). This achieved similar pain scores of 3.2 ± 2.7 and 3.8 ± 2.5 of the 11-point rating scale (p = 0.405). The distribution of KCNJ6 rs2070995 AA carriers differed significantly neither among pain diagnoses (χ 2 test: p = 0.275) nor among opioids (χ 2 tests: p always >0.05).
Miotic effects of levomethadone
Neither the maximum miotic effects nor the areas under the miosis versus time curves were signifi- 
KCNJ6 gene locus
All observed distributions of homozygous or heterozygous carriers of a SNP corresponded to the
Hardy-Weinberg equilibrium (χ 2 -test: p>0.05 for the nine KCNJ6 SNPs diagnosed in healthy volunteers and drug addicts, and p>0.05 for rs2070995 in the pain patients). The distribution of KCNJ6 variant alleles was similar between the cohort of healthy volunteers and the opiate addicts (genotype association tests using χ 2 statistics: p>0.09 at an uncorrected α-level for all KCNJ6 variants, Table 1 ). In-silico haplotype analysis included all nine KCNJ6 genetic variants. One haploblock with high linkage was identified including the SNPs rs2835885A>C, rs1787394T>G, rs10483038A>G and rs702859T>C localized in intron 3 and exon 4, respectively ( Figure 3) . The linkage between the other five SNPs reaching from SNP rs6517442A>G in the 5' UTR up to SNP rs2070995G>A localized in exon 3 was low. Especially, the linkage between the two variants rs6517442A>G and rs2070995G>A reported to compose a functional haplotype [6] was very low with linkage disequilibrium values of r 2 =0.01 and D'=0.13.
Discussion
In an independent cohort we could repeat the finding that the KCNJ6 rs2070995 polymorphism increases opioid dosing demands in homozygous carriers of the minor A allele [6] . The result extends the association of the KCNJ6 rs2070995 AA genotype from increased postoperative opioid requirements to increased dosing requirements during opioid substitution therapy. According to
Cohen's d of >0.8 the effects for opioid dosing for drug substitution are large. However, a comparison between analgesia and substitution therapy is not valid because of the different data qualities and study designs. The effects fit to the decreased opioid effects due to lower expression of an important postsynaptic component of the opioid receptor signaling cascade. In addition, the effects fit to reported importance of Kir3.2 for CNS effects of alcohol [17, 18] and for schizophrenia [19] that partly involve similar molecular systems as addiction. In addition to the decreased methadone effects for heroin substitution, the KCNJ6 variant decreased the incidence of opioid withdrawal
effects. This provides a clinical correlate for the attenuated withdrawal effects in GIRK2/3 knockout mice [20] .
In a further clinical sample, a statistical tendency of p < 0.1 was obtained for an effect for opioid analgesic therapy that pointed in the expected direction. The non-significance with two-sided testing may be attributed to the cross-sectional nature of the sample not ideally suited for genetic assessments. Furthermore, the inclusion of patients receiving various opioid analgesics required opioid conversions, which are estimates derived from several studies including meta-analyses resulting in several equally performing conversion systems [21] . However, such a sample reflects the clinical utility of a genotype in everyday practice and provides therefore valuable information supporting the functional association. According to the accepted interpretation of Cohen's d with a value of d = 0.2 as indicative of a small effect, 0.5 of a medium and 0.8 of a large effect size [22] , the effect sizes for opioid demands for analgesia are small (Cohen's d = 0.42) although slightly larger than in the original paper, where an effect size of 0.25 for postoperative opioid demands was found [6] .
Again, the cross-sectional setting of our cohort 2 obtained from outpatients treatment of all kinds of pain was expected to have resulted in noisier data and therefore the significance level of p = 0.093 can be taken as supportive evidence for a pharmacogenetic effect. Nevertheless, when considering that the same data set has been searched for the effects of several other genotypes [8] , the result would not withhold conservative statistical criteria even when the unidirectional hypothesis allows for single-sided testing and thus a significance was possible. Without the previous finding [6] , the result could hardly be used as a proof for the genetic effect.
The present positive associations were seen only when contrasting homozygous carriers of the KCNJ6 rs2070995 A allele with pooled heterozygous and non-carriers. A gene dose effect or a significant difference between carriers and non-carriers, i.e., pooling heterozygous and homozygous carriers, was not seen (details not shown). This verifies the previous report of a molecular and clinical effect of the variant only when homozygously present [6] .
In contrast to drug substitution and analgesia, the KCNJ6 variant did not significantly modulate the miotic opioid effects of levomethadone. The difference in the maximum miotic effects was even in the wrong direction, i.e., toward increased opioid effects in homozygous carriers of the rs2070995
A allele contrasting to reduced effects in analgesia or opioid substitution therapy. At least the AUC difference was in the expected direction toward smaller opioid effects. With lack of statistical significance for an expected effect, the first possible reason is insufficient sample size. This would have been surprising because pupil size data usually are less noisy than pain data, especially clinical ones, and would also contrast to the results with a positive control genotype (OPRM1 118A>G, rs1799971) from a previous assessment of this data set [9] . However, a sample size calculation to obtain the presently observed difference in pupil size AUCs statistically significant at a power of 0.8 resulted in 231 cases per group. Hardy-Weinberg equilibrium assumed, 231 AA carriers would be found in a random sample of 4367 subjects based on the present minor allele frequency. In contrast, the pupil size data allowed to detect the effect of the OPRM1 rs1799971A>G in this data set [9] with the same number of homozygous carriers as presently found for KCNJ6 rs2070995. When taking only homozygous carriers of the OPRM1 variant, the difference between -110.9±49.1 %·h in OPRM1 rs1799971 GG carriers and -247.2±73.4 %·h in OPRM1 rs1799971 AA/AG carriers was significant at p = 0.003.
Thus, the lacking effect on miosis seemed statistically sound despite the small sample size of homozygous carriers. From this, we abductively reasoned that a likely cause may be the absence of Kir3.2 from the Edinger-Westphal nucleus. This conclusion was subsequently verified by our finding that the neurons of the Edinger-Westphal nucleus indeed lack expression of the Kir3.2 channel protein. For brain structures involved in drug dependence, the positive finding with the drug addicts' data (cohort 1) can be taken as a strong indication that Kir3.2 is expressed in relevant structures of addictive behaviors. This is supported by the finding of Kir3.2 in neurons of the mesolimbic system [23] .
The haplotype rs6517442G/rs2070995A had previously been reported to be also associated with decreased opioid effects [6] . However, the structure of the human KCNJ6 gene judged by the present selection of nine variants showed low linkage between the two variants rs6517442 and rs2070995 suggested to form a functional haplotype. This raises question about the combination of SNPs being a relevant haplotype and raises doubt about the existence of this haplotype, considering the known difficulties of haplotype estimation in the presence of low linkage disequilibrium, stressing the importance of careful consideration of confidence measures when using estimated haplotype frequencies and individual assignments in biomedical research [10] . An exploratory association analysis for this haplotype was negative in all data sets (details not shown). We therefore propose to not further stress the functional importance of that "haplotype".
In conclusion, we could reproduce the association of the KCNJ6 rs2070995 AA genotype with increased opioid requirements. The modulation of opioid effects was extended to methadone substi-tution therapy and consists in increased dosing requirements and reduced withdrawal effects. In addition, based on absent effects on levomethadone induced miosis in a small sample of volunteers and subsequently verified immunohistochemically, we could show that KCNJ6 genetics does not affect pupillary effects of opioids. This emphasizes that opioid effects may be differentially modulated by genetic variants. (Figure 3) . Minor alleles underlined. 
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